Arch Biopartners Inc.
27 St. Clair Avenue East
P.O. Box 305
Toronto
Ontario
M4T 2M5
Canada
Tel: 647-428-7031
Fax: 905-770-4454
Website: http://www.archbiopartners.com/
76 articles about Arch Biopartners Inc.
-
Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST
8/18/2020
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) will host a webinar today at 11:00am EST to present an overview of the LSALT Peptide development program and upcoming Phase II human trial to treat inflammation in patients with severe complications from Covid-19
-
Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST
8/7/2020
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it will host a webinar on August 18, 2020 at 11:00am EST to present an overview of the LSALT Peptide development program and upcoming Phase II human trial to treat inflammation in patients with severe complications from Covid-19. The presenters of the webinar will include key members of the Arch science and management team, including LSALT co-inve
-
Arch Biopartners Receives Independent Institutional Review Board Approval for Phase II Trial for LSALT Peptide
8/4/2020
Arch Biopartners Inc., announced that it received independent Institutional Review Board approval for the Phase II trial of its lead drug LSALT peptide targeting acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19.
-
Broward Health Medical Center Becomes First Clinical Site in U.S. for Phase II Trial for LSALT Peptide
7/28/2020
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced that it has chosen its first U.S. clinical site for the Phase II trial of its lead drug LSALT peptide (Metablok).
-
Arch Biopartners Engages Global CRO to Conduct LSALT peptide (Metablok) Phase II trial for Treatment of Complications in COVID-19 Patients in the U.S.
7/14/2020
Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19)
-
Arch Biopartners Closes Non-Brokered Private Placement
6/30/2020
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has closed the non-brokered private placement the Company disclosed in a press release June 24, 2020 (The “Offering”). Pursuant to the Offering, Arch issued 900,000 common shares priced at CAD $1.50 per common share (the “Common Shares”) for ne
-
Arch Biopartners Arranges Non-Brokered Private Placement
6/24/2020
Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private placement offering of up to 900,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $1,000,000 USD (approximately $1,350,000 CAD) (the “Offering”). The proceeds of
-
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
6/16/2020
International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in patients infected with COVID-19 Novel Mechanism of Action - a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage Study also recently approved by Health Canada TORONTO, June 16, 2020 (GLOBE NEWSWIRE) --
-
Arch Biopartners Announces FDA Acknowledgement of its Investigational New Drug Application for Metablok (LSALT peptide)
6/15/2020
International, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in Patients Infected with SARS-CoV-2 (COVID-19) Novel Mechanism of Action - a selective dipeptidase-1 antagonist that prevents leukocyte adhesion to endothelial cells reducing inflammation and subsequent organ damage Study also recently approved in Canada, additional filings made and planned globa
-
Grant of Options
6/11/2020
Arch Biopartners Inc. announced that its Board of Directors has granted a total of 1,430,000 stock options to directors, officers and certain consultants pursuant to the Company's stock option plan and the requirements of the TSX Venture Exchange.
-
Arch Biopartners Submits Investigational New Drug Application to the FDA for Metablok (LSALT peptide)
6/8/2020
Arch Biopartners Inc. announced it has submitted an Investigational New Drug Application to the U.S. Food and Drug Administration for its lead drug Metablok to conduct a Phase II trial to prevent acute organ inflammation and injury experienced by patients with COVID-19.
-
Arch Biopartners Expands the Primary Endpoint of its Phase II Trial to Include Prevention of Multiple Organ Injuries in Patients with COVID-19
5/19/2020
Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has expanded the primary endpoint of the Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation and injury experienced by patients with COVID-19.
-
Arch Biopartners Receives Health Canada Approval to Conduct COVID-19 Phase II Human Trial
5/8/2020
Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has received a No Objection Letter from Health Canada to conduct a Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation experienced by patients with COVID-19. The Phase II trial will be a multicenter, r
-
Arch Biopartners Releases New Video Showing Metablok Reducing Lung Inflammation in an Animal Model
3/31/2020
Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today released a new video on its website showing the efficacy of its lead drug candidate Metablok in reducing neutrophil recruitment in a mouse model of lung inflammation. The new video can be viewed at the Arch Biopartners website here (click to view) .
-
ARCH BIOPARTNERS SAFELY COMPLETES EXPANDED DOSING OF METABLOK IN PHASE I HUMAN TRIAL AND BEGINS FOCUS ON PHASE II TRIAL
3/17/2020
Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it has safely completed dosing of the final eight healthy volunteers in its Phase I human trial of Metablok (LSALT peptide).
-
Arch Biopartners Expands Dosing in Phase I Trial for Metablok to Increase Dose Range for Future Phase II Studies
3/4/2020
Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it is expanding the dose range of Metablok (LSALT peptide) for future Phase II trials targeting inflammation in the lung, the kidney and/or the liver by adding a cohort of eight healthy volunteers to receive the highest daily dose tested to date for three consecutive days
-
Arch Biopartners Closes Convertible Note Financing - Feb. 06, 2020
2/6/2020
Arch Biopartners Inc.,, announced it has closed the non-brokered, unsecured convertible note financing it disclosed in a press release on February 4th for net proceeds of CAD $500,000.
-
Arch Biopartners Arranges Convertible Note Financing
2/4/2020
TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $500,000 (the “Offering”).
-
Arch Biopartners Announces Metablok Achieves Primary Endpoints of Safety and Tolerability in Phase I Trial
12/18/2019
Metablok is the Company’s lead drug candidate for treating organ damage caused by inflammation
-
Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury
12/4/2019
This is the first patent issued protecting the method of use for the dipeptidase-1 (DPEP-1) inhibitor, cilastatin, for ischemia reperfusion injury, where DPEP-1 mediated inflammation plays a major role.